公开(公告)号：US20240342291A1

公开(公告)日：2024-10-17

申请号：US18681718

申请日：2022-08-05

申请人： UNIVERSITY OF WINDSOR

发明人： Vedran VUKOTIC ,  Jennifer Nicole MURPHY ,  Michelle DAO ,  Joy-Lynn KOBTI

IPC分类号： A61K47/52 ,  A61K47/54

CPC分类号： A61K47/52 ,  A61K47/545

摘要： In a preferred embodiment, there is provided a pharmaceutical coordination composition having a plurality of central atoms or ions, a multitopic ligand and one or more pharmaceutical compounds coordinated to at least one of the plurality of the central atoms or ions, wherein the multitopic ligand is coordinated to at least two of the plurality of central atoms or ions.

公开(公告)号：US11878000B2

公开(公告)日：2024-01-23

申请号：US16343645

申请日：2017-10-21

申请人： Cedars-Sinai Medical Center ,  Da Zen Theranostics, Inc.

发明人： Liyuan Yin ,  Yi Zhang ,  Stefan Mrdenovic ,  Gina Chia Yi Chu ,  Ruoxiang Wang ,  Qinghua Zhou ,  Jian Zhang ,  Leland W. K. Chung

IPC分类号： A61K31/395 ,  A61K31/404 ,  A61P35/00 ,  A61K31/22 ,  A61K31/282 ,  A61K31/337 ,  A61K31/351 ,  A61K31/366 ,  A61K31/47 ,  A61K31/513 ,  A61K47/54 ,  A61P35/04 ,  A61K33/243 ,  A61K31/357 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/65 ,  A61K47/55 ,  A61K47/52 ,  A61K31/4045 ,  A61K31/505 ,  A61K31/555 ,  A61K31/704 ,  A61K31/7068 ,  A61K49/00 ,  C07D493/18 ,  C07D209/10 ,  C07D405/14 ,  A61K31/40 ,  C09B23/01 ,  A61K45/06

CPC分类号： A61K31/404 ,  A61K31/22 ,  A61K31/282 ,  A61K31/337 ,  A61K31/351 ,  A61K31/357 ,  A61K31/366 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/47 ,  A61K31/505 ,  A61K31/513 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/555 ,  A61K31/65 ,  A61K31/704 ,  A61K31/7068 ,  A61K33/243 ,  A61K47/52 ,  A61K47/545 ,  A61K47/55 ,  A61K49/0004 ,  A61K49/0032 ,  A61P35/00 ,  A61P35/04 ,  C07D209/10 ,  C07D405/14 ,  C07D493/18 ,  C09B23/0016 ,  C09B23/0066 ,  A61K45/06 ,  A61K31/4045 ,  A61K2300/00 ,  A61K33/243 ,  A61K2300/00 ,  A61K31/366 ,  A61K2300/00 ,  A61K31/7068 ,  A61K2300/00 ,  A61K31/704 ,  A61K2300/00 ,  A61K31/337 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/47 ,  A61K2300/00 ,  A61K31/22 ,  A61K2300/00 ,  A61K31/505 ,  A61K2300/00 ,  A61K31/555 ,  A61K2300/00 ,  A61K31/282 ,  A61K2300/00

摘要： The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.

公开(公告)号：US20230330261A1

公开(公告)日：2023-10-19

申请号：US17989956

申请日：2022-11-18

申请人： Korea University Research and Business Foundation

发明人： Heemin KANG ,  Sung-Gue LEE ,  Na-Yeon KANG ,  Yu-Ri KIM ,  Hyun-Shik HONG ,  Sang-Hyeok LEE ,  Cho-Won KIM ,  Seong-Yeol KIM

IPC分类号： A61K47/69 ,  A61K47/52

CPC分类号： A61K47/6949 ,  A61K47/52

摘要： Disclosed is a self-assembled complex containing copper ions, including: copper ions; and one or more ligands, in which the ligands and the copper ions are reversibly self-assembled or self-degraded, and when there are a plurality of types of ligands or a plurality of ligands, the shape of the self-assembled complex is formed differently depending on the blending ratio of the ligands.

公开(公告)号：US20230321249A1

公开(公告)日：2023-10-12

申请号：US18013919

申请日：2021-07-01

申请人： Korea Institute of Geoscience and Mineral Resources

发明人： Jae Hwan KIM ,  Il Mo KANG ,  Dae Duk KIM ,  Jang Ik LEE ,  Gyu Ho KIM ,  Min Jun BAEK ,  Chang Yun PARK ,  Ki Min ROH ,  Sung Man SEO

IPC分类号： A61K47/52 ,  A61K47/54

CPC分类号： A61K47/52 ,  A61K47/544

摘要： According to one embodiment of the present invention, provided is a drug-clay mineral complex, in which the complex comprises a phospholipid, and the drug has an amine group.

公开(公告)号：US20230321224A1

公开(公告)日：2023-10-12

申请号：US18063610

申请日：2022-12-08

申请人： Selecta Biosciences, Inc.

发明人： Christopher Fraser ,  Takashi Kei Kishimoto ,  Roberto A. Maldonado

IPC分类号： A61K39/385 ,  A61K39/35 ,  G01N33/50 ,  G01N33/569 ,  A61K39/00 ,  A61K9/127 ,  A61K9/51 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  B82Y5/00 ,  A61K39/36 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K38/18

CPC分类号： A61K39/385 ,  B82Y40/00 ,  G01N33/505 ,  G01N33/56972 ,  A61K39/001 ,  A61K39/0008 ,  A61K9/127 ,  A61K9/5146 ,  A61K38/38 ,  A61K47/50 ,  A61K47/52 ,  A61K47/544 ,  A61K47/593 ,  A61K47/643 ,  A61K47/69 ,  A61K47/6923 ,  A61K47/6929 ,  A61K47/6937 ,  A61K39/00 ,  B82Y5/00 ,  A61K39/36 ,  A61K9/5115 ,  A61K31/192 ,  A61K9/14 ,  A61K38/13 ,  A61K9/5153 ,  A61K38/1816 ,  A61K9/51 ,  G01N2333/70517 ,  G01N2333/70514 ,  G01N2333/7051 ,  A61K2039/5154 ,  A61K2039/577 ,  A61K2039/55511 ,  A61K2039/55555 ,  Y02A50/30 ,  A61K39/35

摘要： Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.

公开(公告)号：US20230293721A1

公开(公告)日：2023-09-21

申请号：US18170229

申请日：2023-02-16

申请人： US Department of the Navy

发明人： James B. Delehanty ,  Megan Muroski ,  Eunkeu Oh ,  Jeffrey R. Deschamps

IPC分类号： A61K47/69 ,  A61K38/17 ,  A61K47/52

CPC分类号： A61K47/6929 ,  A61K38/17 ,  A61K47/52

摘要： A nanoparticle (NP)-peptide conjugate provides efficient steric hindrance/blockage of cellular membrane potassium (K+) channels to mediate depolarization of cellular membrane potential.

公开(公告)号：US20230293698A1

公开(公告)日：2023-09-21

申请号：US17927168

申请日：2021-05-24

申请人： The University of Chicago

发明人： Wenbin Lin ,  Kaiyuan Ni ,  Taokun Luo ,  Guangxu Lan

IPC分类号： A61K47/52 ,  A61P35/00 ,  A61K31/7088

CPC分类号： A61K47/52 ,  A61P35/00 ,  A61K31/7088

摘要： Modified metal-organic framework (MOFs) are described that have surfaces with enhanced ability to coordinatively bond to or electrostatically interact with therapeutic agents, such as nucleic acids and small molecules and proteins with phosphate or carboxylate groups. Methods of providing the modified MOFs are described that include replacing strongly coordinating metal oxo cluster capping groups with weakly coordinating capping groups and/or incorporating organic bridging ligands with electron-withdrawing groups. MOFs with surface attached therapeutic agents (e.g., immunotherapeutic agents) prepared from the modified MOFs are also described, along with methods of using the MOFs as to treat cancer, e.g., via radiotherapy-radiodynamic therapy (RT-RDT), either with or without the co-administration of another therapeutic agent, such as a chemotherapeutic agent or an immunomodulator. Thus, the described methods can involve cancer immunotherapy and in situ cancer vaccination.

公开(公告)号：US11744813B2

公开(公告)日：2023-09-05

申请号：US17519068

申请日：2021-11-04

申请人： OXFORD PHARMASCIENCE LIMITED

发明人： Elizabeth King ,  Marcelo Leonardo Bravo Cordero ,  Ann Taylor-Hutchinson

IPC分类号： A61K31/192 ,  A61K47/02 ,  A61K47/10 ,  A61K47/20 ,  A61K47/24 ,  A61K47/52

CPC分类号： A61K31/192 ,  A61K47/02 ,  A61K47/10 ,  A61K47/20 ,  A61K47/24 ,  A61K47/52

摘要： The invention relates to a composition comprising: i) one or more LDH-active anion materials comprising an LDH matrix intercalated with one or more active anions, and ii) a modifier system comprising a) one or more surfactants, in combination with b) one or more compounds having the generic formula MA, where M comprises one or more positively charged ions and A comprises one or more negatively charged counter ions.

公开(公告)号：US10080808B2

公开(公告)日：2018-09-25

申请号：US15433898

申请日：2017-02-15

申请人： UTI Limited Partnership

发明人： Pedro Santamaria

IPC分类号： A61K39/00 ,  A61K47/69 ,  A61K47/64 ,  A61K47/60

CPC分类号： A61K47/6929 ,  A61K39/0008 ,  A61K47/52 ,  A61K47/60 ,  A61K47/646 ,  A61K47/6923 ,  A61K2039/55555 ,  A61K2039/60 ,  A61K2039/605 ,  A61K2039/627 ,  Y10T428/2982

摘要： This disclosure provides therapeutic compositions and methods for treating multiple sclerosis or a multiple sclerosis-related disorder in a subject in need thereof comprising administering an effective amount of an antigen-MHC-nanoparticle complex to the subject, wherein the antigen is a multiple sclerosis-related antigen.

公开(公告)号：US20180264134A1

公开(公告)日：2018-09-20

申请号：US15768737

申请日：2016-10-17

申请人： CENTRO DE NEUROCIENCIAS E BIOLOGIA CELULAR

发明人： Lino DA SILVA FERREIRA ,  Michela COMUNE

IPC分类号： A61K47/69 ,  A61K35/12 ,  A61P17/02 ,  A61P31/00 ,  A61K35/44 ,  A61K35/36 ,  A61K47/52 ,  A61K38/17

CPC分类号： A61K47/6923 ,  A61K35/12 ,  A61K35/36 ,  A61K35/44 ,  A61K38/1709 ,  A61K38/1729 ,  A61K47/52 ,  A61K47/6929 ,  A61P17/02 ,  A61P31/00

摘要： The present disclosure relates to an antimicrobial peptide conjugated with nanoparticles, in particular the antimicrobial peptide LL37-conjugated gold nanoparticles for use in medicine or cosmetic, for human or animals, namely in the treatment of wound healing or in the treatment of ischemic or vascular diseases, comprising a gold nanoparticle and a plurality of LL-37 peptides, wherein the plurality of LL-37 peptides is bound to the gold nanoparticle surface.